Dianthus Therapeutics Inc... (DNTH)
16.32
1.46 (9.83%)
At close: Apr 09, 2025, 3:59 PM
16.68
2.23%
Pre-market: Apr 10, 2025, 09:06 AM EDT
Company Description
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases.
It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Dianthus Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Marino Garcia M.B.A. |
Contact Details
Address: 7 Times Square New York, New York United States | |
| Website | https://dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer & Director |
| Kristina Maximenko | Chief People Officer |
| Ryan Savitz | Chief Financial Officer & Chief Business Officer |
| Adam M. Veness Esq. | Senior Vice President, General Counsel & Secretary |
| Edward G. Carr | Chief Accounting Officer |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. |
| Judson Taylor | Senior Vice President & Head of Technical Operations |
| Rashieda Gluck | Head of Clinical Development Operations |
| Scott Nogi M.B.A. | Head of Business Operations |
| Simrat Randhawa M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | SCHEDULE 13G | Filing |
| Mar 19, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 11, 2025 | S-8 | Filing |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 3 | Filing |
| Mar 05, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |